As the market for biotech and other medical companies developing vaccines, medicines and medical instruments continues to grow, Goodwin Procter is launching a PropSci practice to handle the industry’s specialized real estate needs.
“Real estate for biotechnology, pharmaceutical and medical device companies has become a class in itself,” said Andy Sucoff, a partner in the firm’s real estate industry group and chair of its Boston office. “We are launching the PropSci practice to meet growing client demand at the intersection of the two industries.”
The market for suitable properties is “white hot” in the United States, and in Europe in ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.